Unstable Angina The Trial: FRISC II Presenters: Lars Wallentin and Bo Lagerqvist, Cardiothoracic Centre, University Hospital, Uppsala, Sweden. The study: A randomized, placebo-controlled trial of lowmolecular-weight heparin (dalteparin) in conjunction with either early revascularization or conservative medical therapy in 2457 patients with unstable angina or non–Q-wave myocardial infarction (MI...

Abstract Introduction Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in inpatients; with those undergoing lower limb surgery at particularly high risk. NICE recommends that Low Molecular Weight Heparin (LMWH) or Fondaparinux should be used for VTE prophylaxis one month following hip fracture. Our local policy to prescribe Dalteparin 30 days surgery. Method A clos...